Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy
📈 AbbVie reported Q1 revenue of $15 billion, beating the $14.72 billion consensus by $280 million.
🧬 Star drugs Skyrizi and Rinvoq drove strong growth, with Skyrizi up 30.9% and Rinvoq up 23.3% year-over-year.
💊 The migraine franchise surged with Qulipta growing 53.6% and Ubrelvy up 41.4%.
🚀 Management raised full-year adjusted EPS guidance to $14.08–$14.28 despite a slight GAAP miss.
⚖️ Shares are currently down 9.3% year-to-date after a 9.3% drop since the end of last year.
💡 The obesity pipeline candidate ABBV-295 showed early clinical benefit in body weight reduction data.
🎯 Oncology drug Elahere demonstrated a greater than 60% objective response rate in platinum-sensitive ovarian cancer.
⬇️ Biosimilar pressure weighs on legacy drugs like Humira, which fell 38.6% to $688 million in revenue.
💸 A $744 million IPR&D charge impacted GAAP earnings but is viewed as a strategic investment rather than core weakness.
👍 Wall Street consensus sees 22 buy ratings versus zero sells, with a price target of $249.27.
📈 Analysts see a high confidence buy rating due to strong growth franchises and compressed valuation multiples.
⚠️ Risks include potential deceleration in immunology growth and additional FDA Complete Response Letters on manufacturing.
💰 The company's forward multiple has compressed to reasonable levels following the stock's decline.
🔮 The obesity pipeline readout later in the year is a key factor that could impact future returns.
👨⚕️ CEO Robert Michael confirmed that key growth drivers are delivering strong performance supporting the enhanced outlook.
- AbbVie (ABBV) reported Q1 revenue of $15B, beating consensus estimates by $280M.
- Skyrizi sales surged 30.9% year-over-year to $4.48B and Rinvoq grew 23.3% to $2.12B.
- Management raised full-year adjusted EPS guidance to a range of $14.08-$14.28, signaling confidence in the company's outlook.
- The migraine franchise showed exceptional growth with Qulipta up 53.6% and Ubrelvy up 41.4%.
- The obesity pipeline candidate ABBV-295 demonstrated clinically meaningful body weight reduction in early clinical data.
- Oncology drug Elahere achieved a >60% objective response rate in platinum-sensitive ovarian cancer trials.
- Wall Street consensus price targets stand at $249.27 with 22 buy ratings and zero sells.
- The company's stock closed up 3.14% following the earnings report, reflecting investor optimism.
- AbbVie's Adjusted EPS of $2.65 missed consensus estimates by $0.02, despite headline revenue beats.
- The company recorded a massive $744 million charge for in-process research and development (IPR&D), which clipped earnings per share by $0.41.
- GAAP net income fell sharply by 45.96% year-over-year, reflecting significant accounting charges rather than just core operational weakness.
- Major revenue franchises are declining: Humira revenue plummeted 38.6% YoY to $688 million, and Imbruvica slid 24.7%. These losses could continue if growth from new drugs like Skyrizi and Rinvoq stalls.
- Regulatory risks remain high, with the FDA issuing a Complete Response Letter on trenibotulinumtoxinE specifically over manufacturing issues, setting a precedent for future approval hurdles.
- Future projections rely heavily on Skyrizi and Rinvoq maintaining robust growth; any material deceleration in these immunology drugs would undermine the bull case.
- Valuation concerns could escalate if additional Complete Response Letters emerge across other portfolio segments or if biosimilar competition intensifies later in the decade.
- Significant downside risks include potential shifts in U.S. drug pricing policy, which could compress margins for key franchises like Skyrizi and Rinvoq.
- The successful progress of the obesity candidate (ABBV-295) through Phase 2 is a critical assumption; failure here would negatively impact the growth pipeline.
